Unaudited Half-Yearly Financial Report for the Six Months Ended 30
September 2024
21 NOVEMBER 2024
NORTHERN 2 VCT PLC
UNAUDITED HALF-YEARLY FINANCIAL REPORT
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Northern 2 VCT PLC is a Venture Capital Trust (VCT) managed by
Mercia Fund Management Limited (the Manager). It invests mainly in
unquoted venture capital holdings and aims to provide long-term
tax-free returns to shareholders through a combination of dividend
yield and capital growth.
Financial highlights (comparative figures as at
30 September 2023 and 31 March 2024)
|
|
Six months ended
30 September
2024 |
Six months ended
30 September
2023 |
Year
ended
31 March
2024 |
Net assets |
|
£127.5m |
£113.9m |
£119.5m |
Net asset value per share |
|
57.2p |
58.6p |
57.3p |
Return per share |
|
|
|
|
Revenue |
|
0.2p |
0.3p |
0.8p |
Capital |
|
0.8p |
0.6p |
0.6p |
Total |
|
1.0p |
0.9p |
1.4p |
Dividend per share declared in respect of the
period |
|
1.7p |
1.8p |
3.0p |
Cumulative return to shareholders since launch |
|
|
|
|
Net asset value per share |
|
57.2p |
58.6p |
57.3p |
Dividends paid per share* |
|
140.3p |
137.3p |
139.1p |
Net asset value plus dividends paid per share |
|
197.5p |
195.9p |
196.4p |
Mid-market share price at end of period |
|
55.0p |
55.0p |
54.5p |
Share price discount to net asset value |
|
3.8% |
6.1% |
4.9% |
Tax-free dividend yield
(based on the net asset value per share)** |
|
5.0% |
5.5% |
5.1% |
* Excluding
interim dividend not yet paid.
** The dividend
yield is calculated by dividing the dividends declared in the 12
month period ended on each reference date by the net asset value
per share at the start of that period.
Enquiries:
James Sly / Sarah Williams, Mercia Asset Management PLC – 0330 223
1430
Website: www.mercia.co.uk/vcts
HALF-YEARLY MANAGEMENT REPORT TO
SHAREHOLDERS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
There have been a significant number of developments in the last
reporting period which are likely to have a long-term impact on
your Company. The global political and economic climate remains
volatile, as a result of conflict in both Europe and the Middle
East and a degree of uncertainty following the US presidential
election. The UK general election delivered a large parliamentary
majority for the Labour party which commentators suggest may create
a period of political stability. It is probably too early to be
entirely clear about the longer term impact of the Chancellor of
the Exchequer’s recent budget, the objective of which was to set a
path of economic growth, which of course aligns closely with your
Company’s core objectives in respect of its investments. Perhaps
most importantly the European Commission confirmed that the VCT
investment schemes, which are so critical to financing early stage
businesses, would be extended until April 2035. There has been some
easing of inflationary pressures and a stabilisation in energy
prices. Interest rates have fallen from the peak, but it is still
uncertain as to how quickly that will continue. Your Company
continues to deliver vital investments into early stage businesses
providing ongoing support to its existing portfolio companies and
generating returns from successful realisations.
Results and dividend
The Company achieved a return of 1.0 pence per share in the period
(2023: 0.9p per share), equivalent to 1.9% of the audited net asset
value (NAV) per share on 31 March 2024. After deducting the final
dividend for the year to 31 March 2024 of 1.2p, paid in August
2024, the NAV per share at 30 September 2024 was
57.2 pence.
It remains our objective to pay a dividend at least equivalent
to 5% of the opening NAV in each year. The Board has declared an
interim dividend for the year ending 31 March 2025 of 1.7 pence per
share, which will be paid on 22 January 2025 to shareholders who
are on the register on 20 December 2024.
Venture capital investment activity and portfolio
update
We are pleased to report that a number of our venture investments
have performed well over the period, reflected in an overall
increase in the valuation of the unquoted portfolio. Where
portfolio companies have struggled or are at risk of failure, we
have also made a number of reductions in valuations to reflect our
current assessment.
The unaudited total (realised and unrealised) gain on
investments for the six month period to 30 September 2024 was £2.4
million (six months ended 30 September 2023: £2.1 million) of which
£0.9 million related to net unrealised gains in the portfolio
driven by commercial traction in several portfolio companies. As is
to be expected in a portfolio of more than 50 companies, these
increases have been partially offset by some value reductions where
particular portfolio companies have struggled or are at risk of
failure. Overall, total returns from the portfolio have shown
resilience against a challenging economic backdrop.
During the reporting period we have continued to achieve
realisations of our portfolio with £6.0 million of realisations.
Notably, the Company’s investment in Gentronix, a biotechnology
company that provides predictive toxicology solutions, was divested
for net proceeds of £5.2 million, representing 4.5 times return on
the original cost. The majority of this substantial gain on sale
had already been reflected in prior accounting periods with £1.3
million of the gain recognised upon exit. Gentronix was one of the
Company’s oldest investments, where the initial investment in 2007
was followed by two additional funding rounds.
Investment activity continued in the period, with £5.9 million
invested across three existing and three new portfolio companies.
The new portfolio companies are Ski Zoom (t/a Heidi) (£1.5 million
investment), a booking platform for flexible winter mountain
breaks, Culture AI (£1.4 million), a cyber security training
and monitoring platform, and Promethean Particles (£1.3 million), a
developer of carbon capture and gas storage technologies. Follow-on
capital of £1.7 million was also deployed to support the Company’s
existing portfolio companies.
Following the period end, we exited one of our larger
investments, The Climbing Hangar, at a modest increase on its
valuation at 31 March 2024 but below cost, at just over 70% of our
total investment cost. Based in Liverpool, we first invested in the
company, which operated three indoor climbing centres, in August
2018 and supported the acquisition of five new sites through three
additional funding rounds. However, Covid lockdowns severely
impacted operations and delayed the company's ability to reach
breakeven, creating a need for more capital investment. The company
reached its limit for VCT funding and we were unable to offer
further financial support. Whilst a disappointing financial result,
the sale enables the company's operations to continue with new
owners which are able to fund the company's continued
expansion.
Shareholder issues
In April 2024 shares related to the second allotment of the 2023/24
share offer, totalling £20 million, were issued. This allotment saw
the issuance of 17,376,231 new ordinary shares, yielding gross
subscriptions of £10.4 million.
Our dividend investment scheme, which enables shareholders to
invest their dividends in new ordinary shares free of dealing costs
and with the benefit of the tax reliefs available on new VCT share
subscriptions, continues to operate, with around 14% of total
dividends reinvested by shareholders during the period.
We continue to experience a sustained demand for long-term
growth capital for smaller companies in the UK. In order to
continue to support our existing portfolio and invest in new
early-stage opportunities, in September 2024 we announced our
intention to fundraise in this current tax year 2024/25. This
fundraise will be in conjunction with the other Northern VCTs and
it is envisaged that the Company will seek to raise up to £15
million, with a total fund raising of up to £36 million across all
Northern VCTs. Full details of how to participate in the fundraise
will be published in January 2025.
We have maintained our policy of being willing to buy back the
Company’s shares in the market when necessary in order to provide
liquidity to our shareholders, at a 5% discount to NAV. During the
period, a total of 3,538,346 shares were repurchased for
cancellation, equivalent to approximately 1.7% of the opening share
capital. As at 30 September 2024, the share price discount to NAV
per share was 3.8%.
VCT qualifying status and legislation
The Company has continued to meet the stringent and complex
qualifying conditions laid down by HM Revenue & Customs for
maintaining its approval as a VCT. The Manager monitors the
position closely and reports regularly to the Board. Philip Hare
& Associates LLP has continued to act as independent adviser to
the Company on VCT taxation matters.
As noted above, we are pleased to report that following final
review by the European Union and the issuance of the necessary
statutory instrument, in September 2024 the Sunset Clause was
extended until 2035. The ‘Sunset Clause’ is a European state aid
requirement which, without extension, would have removed the VCT
tax reliefs that investors receive on newly issued VCT shares.
Board of Directors
In accordance with the details outlined in our Annual Report, we
were pleased to appoint Thomas Chambers to the Board in June
2024.
Outlook
We remain confident in the prospects of our portfolio companies and
will continue to make the most of the opportunities for value
creation as they arise.
The Board very much appreciates the continuing support of
shareholders.
On behalf of the Board
David Gravells
Chair
Investment portfolio
As at 30 September 2024 (unaudited)
|
Cost
£000 |
Valuation
£000 |
% of net assets
by value |
Fifteen largest venture capital investments |
|
|
|
Pure Pet Food |
1,504 |
3,807 |
3.0% |
Project Glow Topco (t/a Currentbody.com) |
1,544 |
3,530 |
2.8% |
Rockar |
1,766 |
3,244 |
2.5% |
Pimberly |
1,876 |
3,188 |
2.5% |
Tutora (t/a Tutorful) |
3,023 |
3,023 |
2.4% |
Newcells Biotech |
2,741 |
2,741 |
2.1% |
Grip-UK (t/a The Climbing Hangar) |
3,536 |
2,568 |
2.0% |
Netacea |
2,486 |
2,486 |
1.9% |
Ridge Pharma |
1,387 |
2,396 |
1.9% |
Biological Preparations Group |
2,166 |
2,028 |
1.6% |
Broker Insights |
1,961 |
2,001 |
1.6% |
Volumatic Holdings |
216 |
1,869 |
1.5% |
Administrate |
2,629 |
1,855 |
1.5% |
LMC Software |
1,842 |
1,842 |
1.4% |
Forensic Analytics |
1,836 |
1,836 |
1.4% |
Fifteen largest venture capital investments |
30,513 |
38,414 |
30.1% |
Other venture capital investments |
49,824 |
39,642 |
31.1% |
Total venture capital investments |
80,337 |
78,056 |
61.2% |
Net current assets |
|
49,489 |
38.8% |
Net assets |
|
127,545 |
100.0% |
Extracts from the unaudited half-yearly
financial statements for the six months ended 30 September 2024 are
set out below.
Income statement
For the six months ended 30 September 2024 (unaudited)
|
Six months
ended 30 September 2024 |
|
Six months
ended 30 September 2023 |
|
Year ended
31 March 2024 |
Revenue
£000 |
Capital
£000 |
Total
£000 |
|
Revenue
£000 |
Capital
£000 |
Total
£000 |
|
Revenue
£000 |
Capital
£000 |
Total
£000 |
Gain on disposal of investments |
– |
1,469 |
1,469 |
|
– |
518 |
518 |
|
– |
933 |
933 |
Movements in fair value of investments |
– |
884 |
884 |
|
– |
1,533 |
1,533 |
|
– |
1,839 |
1,839 |
|
– |
2,353 |
2,353 |
|
– |
2,051 |
2,051 |
|
– |
2,772 |
2,772 |
|
|
|
|
|
|
|
|
|
|
|
|
Dividend and interest income |
1,349 |
– |
1,349 |
|
1,123 |
– |
1,123 |
|
2,738 |
– |
2,738 |
Investment management fee |
(277) |
(832) |
(1,109) |
|
(258) |
(775) |
(1,033) |
|
(515) |
(1,545) |
(2,060) |
Other expenses |
(332) |
– |
(332) |
|
(322) |
– |
(322) |
|
(602) |
– |
(602) |
|
|
|
|
|
|
|
|
|
|
|
|
Return before tax |
740 |
1,521 |
2,261 |
|
543 |
1,276 |
1,819 |
|
1,621 |
1,227 |
2,848 |
Tax on return |
(187) |
187 |
– |
|
81 |
(81) |
– |
|
73 |
(73) |
– |
|
|
|
|
|
|
|
|
|
|
|
|
Return after tax |
553 |
1,708 |
2,261 |
|
624 |
1,195 |
1,819 |
|
1,694 |
1,154 |
2,848 |
|
|
|
|
|
|
|
|
|
|
|
|
Return per share |
0.2p |
0.8p |
1.0p |
|
0.3p |
0.6p |
0.9p |
|
0.8p |
0.6p |
1.4p |
Balance sheet
As at 30 September 2024 (unaudited)
|
|
30 September 2024
£000 |
30 September 2023
£000 |
31 March
2024
£000 |
Fixed assets |
|
|
|
|
Investments |
|
78,056 |
66,265 |
75,779 |
Current assets |
|
|
|
|
Debtors |
|
640 |
396 |
911 |
Cash and cash equivalents |
|
49,023 |
47,367 |
42,999 |
|
|
49,663 |
47,763 |
43,910 |
|
|
|
|
|
Creditors (amounts falling due within one
year) |
|
(174) |
(141) |
(163) |
Net current assets |
|
49,489 |
47,622 |
43,747 |
|
|
|
|
|
Net assets |
|
127,545 |
113,887 |
119,526 |
|
|
|
|
|
Capital and reserves |
|
|
|
|
Called-up equity share capital |
|
11,159 |
9,722 |
10,434 |
Share premium |
|
62,193 |
43,847 |
52,737 |
Capital redemption reserve |
|
1,256 |
957 |
1,079 |
Capital reserve |
|
54,405 |
64,843 |
54,973 |
Revaluation reserve |
|
(2,281) |
(6,195) |
(853) |
Revenue reserve |
|
813 |
713 |
1,156 |
Total equity shareholders’ funds |
|
127,545 |
113,887 |
119,526 |
|
|
|
|
|
Net asset value per share |
|
57.2p |
58.6p |
57.3p |
Statement of changes in equity
For the six months ended 30 September 2024 (unaudited)
|
Non-distributable reserves |
|
Distributable reserves |
|
Total
£000
|
Called-up
share capital
£000 |
Share
premium
£000 |
Capital
redemption
reserve
£000 |
Revaluation
reserve*
£000 |
|
Capital
reserve
£000 |
Revenue
reserve
£000 |
|
At 1 April 2024 |
10,434 |
52,737 |
1,079 |
(853) |
|
54,973 |
1,156 |
|
119,526 |
Return after tax |
– |
– |
– |
(1,428) |
|
3,136 |
553 |
|
2,261 |
Dividends paid |
– |
– |
– |
– |
|
(1,791) |
(896) |
|
(2,687) |
Net proceeds of share issues |
902 |
9,456 |
– |
– |
|
– |
– |
|
10,358 |
Shares purchased for cancellation |
(177) |
– |
177 |
– |
|
(1,913) |
– |
|
(1,913) |
|
|
|
|
|
|
|
|
|
|
At 30 September 2024 |
11,159 |
62,193 |
1,256 |
(2,281) |
|
54,405 |
813 |
|
127,545 |
Six months ended 30 September 2023
At 1 April 2023 |
9,282 |
38,165 |
849 |
2,015 |
|
59,176 |
89 |
|
109,576 |
Return after tax |
– |
– |
– |
(8,210) |
|
9,405 |
624 |
|
1,819 |
Dividends paid |
– |
– |
– |
– |
|
(2,531) |
– |
|
(2,531) |
Net proceeds of share issues |
548 |
5,682 |
– |
– |
|
– |
– |
|
6,230 |
Shares purchased for cancellation |
(108) |
– |
108 |
– |
|
(1,207) |
– |
|
(1,207) |
|
|
|
|
|
|
|
|
|
|
At 30 September 2023 |
9,722 |
43,847 |
957 |
(6,195) |
|
64,843 |
713 |
|
113,887 |
Year ended 31 March 2024
At 1 April 2023 |
9,282 |
38,165 |
849 |
2,015 |
|
59,176 |
89 |
|
109,576 |
Return after tax |
– |
– |
– |
(2,868) |
|
4,022 |
1,694 |
|
2,848 |
Dividends paid |
– |
– |
– |
– |
|
(5,664) |
(627) |
|
(6,291) |
Net proceeds of share issues |
1,382 |
14,572 |
– |
– |
|
– |
– |
|
15,954 |
Shares purchased for cancellation |
(230) |
– |
230 |
– |
|
(2,561) |
– |
|
(2,561) |
|
|
|
|
|
|
|
|
|
|
At 31 March 2024 |
10,434 |
52,737 |
1,079 |
(853) |
|
54,973 |
1,156 |
|
119,526 |
.
Statement of cash flows
For the six months ended 30 September 2024 (unaudited)
|
|
Six months
ended
30 September
2024
£000 |
Six months
ended
30 September
2023
£000 |
Year ended
31 March 2024
£000 |
Cash flows from operating activities |
|
|
|
|
Return before tax |
|
2,261 |
1,819 |
2,848 |
Adjustments for: |
|
|
|
|
Gain on disposal of investments |
|
(1,469) |
(518) |
(933) |
Gain in fair value of investments |
|
(884) |
(1,533) |
(1,839) |
(Increase)/decrease in debtors |
|
271 |
(278) |
(85) |
Increase/(decrease) in creditors |
|
11 |
(33) |
(11) |
|
|
|
|
|
Net cash inflow/(outflow) from operating
activities |
|
190 |
(543) |
(20) |
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Purchase of investments |
|
(5,940) |
(5,715) |
(15,569) |
Sale and repayment of investments |
|
6,016 |
21,815 |
22,168 |
|
|
|
|
|
Net cash inflow/(outflow) from investing
activities |
|
76 |
16,100 |
6,599 |
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Issue of ordinary shares |
|
10,802 |
6,389 |
16,507 |
Share issue expenses |
|
(444) |
(159) |
(553) |
Purchase of ordinary shares for cancellation |
|
(1,913) |
(1,207) |
(2,561) |
Equity dividends paid |
|
(2,687) |
(2,531) |
(6,291) |
|
|
|
|
|
Net cash inflow/(outflow) from financing
activities |
|
5,758 |
2,492 |
7,102 |
|
|
|
|
|
Net increase in cash and cash equivalents |
|
6,024 |
18,049 |
13,681 |
Cash and cash equivalents at beginning of period |
|
42,999 |
29,318 |
29,318 |
|
|
|
|
|
Cash and cash equivalents at end of period |
|
49,023 |
47,367 |
42,999 |
Risk management
The Board carries out a regular and robust assessment of the risk
environment in which the Company operates and seeks to identify new
risks as they emerge. The principal and emerging risks and
uncertainties identified by the Board which might affect the
Company’s business model and future performance, and the steps
taken with a view to their mitigation, are as follows:
Credit risk: the Company holds a number of
financial instruments and cash deposits and is dependent on the
counterparties discharging their commitment. Such balances may be
held with banks or in money market funds as part of the Company’s
liquidity management.
Mitigation: the Directors review the creditworthiness of the
counterparties to these instruments including the rating of money
market funds to seek to manage and mitigate exposure to credit
risk.
Economic and geopolitical risk: events such as
economic recession or general fluctuation in stock markets,
exchange rates and interest rates may affect the valuation of
investee companies and their ability to access adequate financial
resources, as well as affecting the Company’s own share price and
discount to net asset value. The level of economic risk is assessed
against macroeconomic factors such as inflation, interest rates and
the ability of companies to raise funds in the capital and private
markets.
Mitigation: the Company invests in a diversified portfolio of
investments spanning various industry sectors and which are at
different stages of growth. The Company maintains sufficient cash
reserves to be able to provide additional funding to investee
companies where it is appropriate and in the interests of the
Company to do so. The Manager’s team is structured such that
appropriate monitoring and oversight is undertaken by an
experienced investment executive. As part of this oversight, the
investment executive will guide and support the board of each
unquoted investee company. At all times, and particularly during
periods of heightened economic uncertainty, the investment team of
the Manager share best practice from across the portfolio with the
management teams in order to help with addressing economic
challenges.
Financial risk: most of the Company’s
investments involve a medium to long-term commitment and many are
illiquid.
Mitigation: the Directors consider that it is inappropriate to
finance the Company’s activities through borrowing except on an
occasional short-term basis. Accordingly they seek to maintain a
proportion of the Company’s assets in cash or cash equivalents in
order to be in a position to pursue new unquoted investment
opportunities and to make follow-on investments in existing
portfolio companies. The Company has very little direct exposure to
foreign currency risk and does not enter into derivative
transactions.
Investment and liquidity risk: the Company
invests in early stage companies which may be pre-revenue at the
point of investment. Portfolio companies may also require
significant funds, through multiple funding rounds to develop their
technology or the products being developed may be subject to
regulatory approvals before they can be launched into the market.
This involves a higher degree of risk and company failure compared
to investment in larger companies with established business models.
Early stage companies generally have limited product lines, markets
and financial resources and may be more dependent on key
individuals. The securities of companies in which the Company
invests are typically unlisted, making them particularly illiquid
and may represent minority stakes, which may cause difficulties in
valuing and disposing of the securities. The Company may invest in
businesses whose shares are quoted on AIM however this may not mean
that they can be readily traded and the spread between the buying
and selling prices of such shares may be wide.
Mitigation: the Directors aim to limit the investment and
liquidity risk through regular monitoring of the investment
portfolio and oversight of the Manager who is responsible for
managing the funds in accordance with the Company’s investment
objective. The investment and liquidity risks are mitigated through
the careful selection, close monitoring and timely realisation of
investments, by carrying out rigorous due diligence procedures and
maintaining a wide spread of holdings in terms of financing stage
and industry sector within the rules of the VCT scheme. The Board
reviews the investment portfolio and liquidity with the Manager on
a regular basis.
Legislative and regulatory risk: in order to
maintain its approval as a VCT, the Company is required to comply
with current VCT legislation in the UK. Changes to UK legislation
in the future could have an adverse effect on the Company’s ability
to achieve satisfactory investment returns whilst retaining its VCT
approval.
Mitigation: the Board and the Manager monitor political
developments and where appropriate seek to make representations
either directly or through relevant trade bodies.
Operational risk: the Company does not have any
employees and the Board relies on a number of third party
providers, including the Manager, registrar. listed investments
custodian, sponsor, receiving agent, lawyers and tax advisers, to
provide it with the necessary services to operate. Such operations
delegated to the Company’s key service providers may not be
performed in a timely or accurate manner, resulting in
reputational, regulatory, or financial damage. The risk of
cyber-attack or failure of the systems and controls at any of the
Company’s third party providers may lead to an inability to service
shareholder needs adequately, to provide accurate reporting and
accounting and to ensure adherence to all VCT legislation
rules.
Mitigation: the Board has appointed an Audit and Risk Committee,
who monitor the effectiveness of the system of internal controls,
both financial and non-financial, operated by the Company and the
Manager. These controls are designed to ensure that the Company’s
assets are safeguarded and that proper accounting records are
maintained. Third party suppliers are required to have in place
their own risk and controls framework, business continuity plans
and the necessary expertise and resources to ensure that a high
quality service can be maintained even under stressed
scenarios.
Stock market risk: a small proportion of the
Company’s investments are quoted on AIM and will be subject to
market fluctuations upwards and downwards. External factors such as
terrorist activity, political activity or global health crises, can
negatively impact stock markets worldwide. In times of adverse
sentiment there may be very little, if any, market demand for
shares in smaller companies quoted on AIM.
Mitigation: the Company’s small number of holdings of quoted
investments are actively managed by the Manager, and the Board
keeps the portfolio and the actions taken under ongoing review.
VCT qualifying status risk: while it is the
intention of the Directors that the Company will be managed so as
to continue to qualify as a VCT, there can be no guarantee that
this status will be maintained. A failure to continue meeting the
qualifying requirements could result in the loss of VCT tax relief,
the Company losing its exemption from corporation tax on capital
gains, to shareholders being liable to pay income tax on dividends
received from the Company and, in certain circumstances, to
shareholders being required to repay the initial income tax relief
on their investment.
Mitigation: the Manager keeps the Company’s VCT qualifying
status under continual review and its reports are reviewed by the
Board on a quarterly basis. The Board has also retained Philip Hare
& Associates LLP to undertake an independent VCT status
monitoring role.
The Board continually assesses and monitors emerging risks that
could impact the Company's operations and strategic objectives. As
part of the risk assessment process, the Board evaluates a wide
range of potential threats and uncertainties that may arise from
evolving market dynamics, regulatory changes, technological
advancements such as artificial intelligence, geopolitical
developments, and other external factors. By remaining aware of
emerging risks, the Board ensures that the Company is better
equipped to anticipate challenges and adapt swiftly to changing
circumstances.
Other Matters
The unaudited half-yearly financial statements for the six
months ended 30 September 2024 do not constitute statutory
financial statements within the meaning of Section 434 of the
Companies Act 2006, have not been reviewed or audited by the
Company’s independent auditor and have not been delivered to the
Registrar of Companies. The comparative figures for the year ended
31 March 2024 have been extracted from the audited financial
statements for that year, which have been delivered to the
Registrar of Companies; the independent auditor’s report on those
financial statements (i) was unqualified, (ii) did not include any
reference to matters to which the auditor drew attention by way of
emphasis without qualifying the report and (iii) did not contain a
statement under Section 498 (2) or (3) of the Companies Act 2006.
The half-yearly financial statements have been prepared on the
basis of the accounting policies set out in the annual financial
statements for the year ended 31 March 2024.
Each of the Directors confirm that to the best of their
knowledge the half-yearly financial statements have been prepared
in accordance with the Statement “Half-yearly financial reports”
issued by the UK Accounting Standards Board and the half-yearly
financial report includes a fair review of the information required
by (a) DTR 4.2.7R of the Disclosure Rules and Transparency Rules,
being an indication of important events that have occurred during
the first six months of the financial year and their impact on the
condensed set of financial statements, and a description of the
principal risks and uncertainties for the remaining six months of
the year, and (b) DTR 4.2.8R of the Disclosure Rules and
Transparency Rules, being related party transactions that have
taken place in the first six months of the current financial year
and that have materially affected the financial position or
performance of the entity during that period, and any changes in
the related party transactions described in the last annual report
that could do so.
The directors of the company at the date of this statement were
Mr D P A Gravells (Chair), Mr T W Chambers, Mr S P Devonshire, Miss
C A McAnulty and Ms R K Ramparia.
The calculation of return per share is based on the return after
tax for the six months ended 30 September 2024 and on 224,542,017
(30 September 2023: 195,318,553) ordinary shares, being the
weighted average number of shares in issue during the period.
The calculation of net asset value per share is based on the net
assets at 30 September 2024 divided by the 223,175,719 (30
September 2023: 194,443,120) ordinary shares in issue at that
date.
The interim dividend of 1.7 pence per share for the year ending
31 March 2025 will be paid on 22 January 2025 to shareholders on
the register on 20 December 2024.
Copies of this half-yearly report will be available to the
public at the Company’s registered office, and on the Company’s
website at www.mercia.co.uk/vcts/n2vct/.
The contents of the Mercia Asset Management PLC
website and the contents of any website accessible from hyperlinks
on the Mercia Asset Management PLC website (or any other website)
are not incorporated into, nor form part of, this announcement.
Northern 2 Vct (LSE:NTV)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Northern 2 Vct (LSE:NTV)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024